Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

By Michael F. Green, K. Nuechterlein, J. Gold, Deanna M. Barch, J. Cohen, S. Essock, W. Fenton, F. Frese, Terry E. Goldberg, R. Heaton and 7 more. Biological Psychiatry, 2004

935 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/0e6d4963e84060ba4bb3c6df3ceb5d890ed9c7ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

In Psychiatry and Mental health

Citations in the corpus

Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model (2008, background): “2 microdeletion also show a spectrum of deficits in cognitive tasks linked to activity in prefrontal cortex (PFC) and hippocampus, such as measures of attention, working memory, executive function and short-term verbal memor”
Identification of separable cognitive factors in schizophrenia. (2004, methodology): “…consensus cognitive battery for schizophrenia: tee decided that the next step in the construction of the battery was to consider candidate tests within each of these seven domains, using the criteria for test selection that we have described elsewhere (Green et al., 2004; Kern et al., 2004).”
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. (2004, background): “At the MATRICS meeting in April 2003 (see summary in Green et al., 2004), a key discussion point was whether changes in cognitive performance alone should be sufficient for a drug to receive approval from the U.S. Food and Drug Administration (FDA).”
Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. (2006, background): “This evidence includes (1) that cognitive deficits are a core feature of schizophrenia and may be associated with genetic vulnerability to the illness, (2) that research on the neuropharmacology of cognition has increased,12 and ( 3 ) that there is a relationship between cog-”
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. (2008, background): “One clear point to emerge from the MATRICS consensus meetings was the importance of reliable and valid assessment of cognitive functioning at the level of key cognitive domains (1, 4).”
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. (2008, methodology): “resented in the MATRICS Consensus Cognitive Battery for clinical trials in schizophrenia.(9,10) Second, so-”